New Technology– category –
-
2026 ‘In Vivo CRISPR Medicine’ Symposium to Focus on Commercialization and Scalable Deployment of In Vivo Genome Editing
CRISPR Medicine News (CMN x CSGCT Virtual Symposium) USA Overview The upcoming 'In Vivo CRISPR Medicine: From Scientific Promise to Patients at Scale' virtual symposium on September 3, 2026, will highlight the transition of in vivo genom... -
CRDWC 2026 Symposium to Address CAR-T Challenges in Solid Tumors: Focus on Design, Manufacturing, and Safety Strategies
CRDWC 2026 (Cancer Research and Development Conference 2026) Unknown Overview The 2026 Cancer Research and Development Conference will host a symposium dedicated to expanding CAR-T cell therapy from hematological malignancies to solid tu... -
Next-Generation Bioinks Create New Opportunities in Tissue Engineering and Drug Discovery via 3D Bioprinting
ACS Publications USA Overview Advances in next-generation bioinks are significantly propelling the fields of tissue engineering and regenerative medicine through 3D bioprinting technology. These bioinks are essential for creating microen... -
Penn State Team Establishes Foundation for 3D Bioprinted Spheroids to Promote Bone Tissue Regeneration and Vascularization
Penn State News USA Overview An interdisciplinary team at Penn State University has laid the groundwork for 3D printing spheroids, small living cell clusters, capable of regenerating bone tissue following severe trauma or infection. Rese... -
Chinese iPSC-Derived Cardiomyocyte Therapy Significantly Improves Heart Function in 90% of Heart Failure Patients in Landmark Phase 2 Trial, Published in Nature Medicine
South China Morning Post China Overview A groundbreaking Phase 2 clinical trial conducted by Nanjing Drum Tower Hospital in China reported that 90% of heart failure patients who received iPSC-derived cardiomyocyte injections showed signi... -
Allogene Therapeutics’ TALEN-Edited Lymphoma Cell Therapy cema-cel Receives FDA RMAT and Fast Track Designations, Achieves 58.3% MRD Negativity in Phase 2 Trial
PRISM MarketView USA Overview Allogene Therapeutics' TALEN-edited allogeneic cell therapy, cema-cel, has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA, accelerating its regulatory pa... -
Bayer Continues Support for BlueRock Therapeutics’ CLARICO Eye Study of iPSC-Derived Photoreceptor Therapy OpCT-001 for Genetic Ocular Disease
TipRanks USA Overview Bayer AG announced continued support for BlueRock Therapeutics' CLARICO eye study, a Phase 1/2a trial evaluating the safety and early efficacy signals of OpCT-001, an iPSC-derived photoreceptor progenitor cell thera... -
3D Bioprinting Advances Tumor Organoid Modeling and Bone Regeneration Spheroids
PMC - NIH USA Overview 3D bioprinting technology is revolutionizing cancer modeling by enabling the construction of human tumor organoids that accurately recapitulate complex tumor microenvironments for high-throughput drug screening. Co... -
Velaura AI Secures $110 Million Series A at $1+ Billion Valuation for Ultra-Low-Power AI Compute, Targeting 2-4x Performance Per Watt
Pulse 2.0 / Morningstar USA Overview Velaura AI has successfully closed a $110 million Series A funding round, valuing the company at over $1 billion, to commercialize its ultra-low-power computing technology for AI data centers, robotic... -
OpenAI, SB Energy, and NVIDIA Partner to Secure 8 Gigawatts of AI Compute Infrastructure at PORTS-Pike Campus
OpenAI official announcement USA Overview OpenAI, in collaboration with SB Energy, NVIDIA, and the U.S. Department of Energy, has signed an agreement to secure approximately 8 gigawatts (GW) of IT capacity at the PORTS-Pike Technology Ca...
